Wednesday, 14 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 4, 2026

McDonald's Value Push New Under $3 Menu And $4 Breakfast Deal

View original at finance.yahoo.com
McDonald's Value Push New Under $3 Menu And $4 Breakfast Deal Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The degree to which customers respond to clearer everyday value, and how franchisee economics hold up under this pricing approach, are likely to be key themes to monitor in upcoming updates from the company

    60% confidence
  • The market has already priced in substantial long term value creation and is also reacting to shorter term pressure on the business and consumer sentiment

    60% confidence
  • If heavier value offers reduce restaurant level profitability, that would challenge the narrative that technology, scale and an asset light model alone are enough to offset cost pressures

    60% confidence
  • The company is shifting away from heavy digital couponing toward more predictable everyday pricing, with support from franchisees

    60% confidence
  • A simplified, standardized value ladder across the U.S. removes some of the complexity of digital-only discounts and makes it easier for customers to understand what they can get for a set spend

    60% confidence

Data points we hold from this source

McDonald's Corporation · stock return 30d-7.5 percent
McDonald's Corporation · stock return 5y49.4 percent
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com